Hung-Jui Tan1, Leonard S Marks2, Michael A Hoyt3, Lorna Kwan2, Christopher P Filson2, Malu Macairan2, Patricia Lieu2, Mark S Litwin4, Annette L Stanton5. 1. Veterans Affairs/UCLA Robert Wood Johnson Clinical Scholars Program, University of California-Los Angeles, Los Angeles, California; Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California. Electronic address: htan@mednet.ucla.edu. 2. Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California. 3. Department of Psychology, Hunter College, City University of New York, New York, New York. 4. Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California; Department of Health Policy and Management, Fielding School of Public Health, University of California-Los Angeles, Los Angeles, California. 5. Departments of Psychology and Psychiatry/Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, California; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California.
Abstract
PURPOSE: Anxiety may serve as a major barrier to participation in active surveillance. Intolerance of uncertainty, that is the tendency to perceive the potential for negative events as threatening, has been linked to cancer related worry. Accordingly we explored prospectively the relationship of intolerance of uncertainty with anxiety along with other clinical factors among men treated with active surveillance for prostate cancer. MATERIALS AND METHODS: A total of 119 men with D'Amico low risk prostate cancer participating in active surveillance completed the HADS (Hospital Anxiety and Depression Scale), MAX-PC (Memorial Anxiety Scale for Prostate Cancer), IUS (Intolerance of Uncertainty Scale) and I-PSS (International Prostate Symptom Score) surveys from 2011 to 2014. We evaluated the relationship between anxiety and IUS score after adjusting for patient characteristics, cancer information and I-PSS using bivariable and multivariable analyses. RESULTS: Of the men 18 (15.1%) and 17 (14.3%) reported clinically significant anxiety on the generalized and prostate cancer specific scales, respectively. On bivariable analysis men with moderate/severe urinary symptoms and higher IUS scores reported more generalized and prostate cancer specific anxiety than men with mild urinary symptoms and lower IUS scores, respectively (p ≤0.008). Men with depressive symptoms (p = 0.024) or a family history of prostate cancer (p = 0.006) experienced greater generalized anxiety. On multivariable analysis IUS score was significantly associated with generalized and prostate cancer specific anxiety (OR 1.22, 95% CI 1.09-1.38 and OR 1.29, 95% CI 1.13-1.49, respectively) while moderate/severe urinary symptoms were associated with prostate cancer specific anxiety (OR 6.89, 95% CI 1.33-35.68). CONCLUSIONS: Intolerance of uncertainty and urinary symptoms may promote anxiety in men on active surveillance for prostate cancer. Patient education, management of lower urinary tract symptoms and behavioral interventions may lessen anxiety related to uncertainty intolerance and help maintain patient engagement in active surveillance.
PURPOSE:Anxiety may serve as a major barrier to participation in active surveillance. Intolerance of uncertainty, that is the tendency to perceive the potential for negative events as threatening, has been linked to cancer related worry. Accordingly we explored prospectively the relationship of intolerance of uncertainty with anxiety along with other clinical factors among men treated with active surveillance for prostate cancer. MATERIALS AND METHODS: A total of 119 men with D'Amico low risk prostate cancer participating in active surveillance completed the HADS (Hospital Anxiety and Depression Scale), MAX-PC (Memorial Anxiety Scale for Prostate Cancer), IUS (Intolerance of Uncertainty Scale) and I-PSS (International Prostate Symptom Score) surveys from 2011 to 2014. We evaluated the relationship between anxiety and IUS score after adjusting for patient characteristics, cancer information and I-PSS using bivariable and multivariable analyses. RESULTS: Of the men 18 (15.1%) and 17 (14.3%) reported clinically significant anxiety on the generalized and prostate cancer specific scales, respectively. On bivariable analysis men with moderate/severe urinary symptoms and higher IUS scores reported more generalized and prostate cancer specific anxiety than men with mild urinary symptoms and lower IUS scores, respectively (p ≤0.008). Men with depressive symptoms (p = 0.024) or a family history of prostate cancer (p = 0.006) experienced greater generalized anxiety. On multivariable analysis IUS score was significantly associated with generalized and prostate cancer specific anxiety (OR 1.22, 95% CI 1.09-1.38 and OR 1.29, 95% CI 1.13-1.49, respectively) while moderate/severe urinary symptoms were associated with prostate cancer specific anxiety (OR 6.89, 95% CI 1.33-35.68). CONCLUSIONS: Intolerance of uncertainty and urinary symptoms may promote anxiety in men on active surveillance for prostate cancer. Patient education, management of lower urinary tract symptoms and behavioral interventions may lessen anxiety related to uncertainty intolerance and help maintain patient engagement in active surveillance.
Authors: B F Hankey; E J Feuer; L X Clegg; R B Hayes; J M Legler; P C Prorok; L A Ries; R M Merrill; R S Kaplan Journal: J Natl Cancer Inst Date: 1999-06-16 Impact factor: 13.506
Authors: Stacy A Eisenberg; Keiko Kurita; Megan Taylor-Ford; David B Agus; Mitchell E Gross; Beth E Meyerowitz Journal: Psychooncology Date: 2014-06-02 Impact factor: 3.894
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: R Ganzer; T Franiel; J Köllermann; T Kuru; D Baumunk; A Blana; B Hadaschik; J von Hardenberg; T Henkel; K-U Köhrmann; U-B Liehr; S Machtens; A Roosen; G Salomon; H-P Schlemmer; L Sentker; J Wendler; U Witzsch; M Schostak Journal: Urologe A Date: 2017-10 Impact factor: 0.639
Authors: Valentin H Meissner; Kathleen Herkommer; Birgitt Marten-Mittag; Jürgen E Gschwend; Andreas Dinkel Journal: J Cancer Surviv Date: 2017-05-21 Impact factor: 4.442
Authors: Peter S Kirk; Kehao Zhu; Yingye Zheng; Lisa F Newcomb; Jeannette M Schenk; James D Brooks; Peter R Carroll; Atreya Dash; William J Ellis; Christopher P Filson; Martin E Gleave; Michael Liss; Frances Martin; Jesse K McKenney; Todd M Morgan; Peter S Nelson; Ian M Thompson; Andrew A Wagner; Daniel W Lin; John L Gore Journal: Cancer Date: 2021-09-13 Impact factor: 6.860
Authors: Nicci Bartley; Christine E Napier; Zoe Butt; Timothy E Schlub; Megan C Best; Barbara B Biesecker; Mandy L Ballinger; Phyllis Butow Journal: Front Psychol Date: 2021-04-22
Authors: Claire Kim; Frances C Wright; Nicole J Look Hong; Gary Groot; Lucy Helyer; Pamela Meiers; May Lynn Quan; Robin Urquhart; Rebecca Warburton; Anna R Gagliardi Journal: PLoS One Date: 2018-02-05 Impact factor: 3.240
Authors: L Bourke; R Stevenson; R Turner; R Hooper; P Sasieni; R Greasley; D Morrissey; M Loosemore; A Fisher; H Payne; S J C Taylor; D J Rosario Journal: Sci Rep Date: 2018-05-30 Impact factor: 4.379
Authors: Nima Aghdam; Abigail Pepin; David Buchberger; Jason Hirshberg; Siyuan Lei; Marilyn Ayoob; Malika Danner; Thomas Yung; Deepak Kumar; Brian T Collins; John Lynch; Shaan Kataria; Simeng Suy; Sean P Collins Journal: Front Oncol Date: 2020-07-03 Impact factor: 6.244
Authors: E Shelley Hwang; Terry Hyslop; Thomas Lynch; Elizabeth Frank; Donna Pinto; Desiree Basila; Deborah Collyar; Antonia Bennett; Celia Kaplan; Shoshana Rosenberg; Alastair Thompson; Anna Weiss; Ann Partridge Journal: BMJ Open Date: 2019-03-12 Impact factor: 2.692